I. Kuss

1.2k total citations
29 papers, 976 citations indexed

About

I. Kuss is a scholar working on Immunology, Oncology and Gastroenterology. According to data from OpenAlex, I. Kuss has authored 29 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 8 papers in Oncology and 7 papers in Gastroenterology. Recurrent topics in I. Kuss's work include Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (8 papers) and Gastrointestinal Tumor Research and Treatment (7 papers). I. Kuss is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (8 papers) and Gastrointestinal Tumor Research and Treatment (7 papers). I. Kuss collaborates with scholars based in United States, Austria and Italy. I. Kuss's co-authors include William E. Gooding, Theresa L. Whiteside, Robert L. Ferris, Bridget Hathaway, Theresa L. Whiteside, Takashi Saito, Thomas Bauernhofer, Grzegorz Dworacki, Andrew S. Baum and Brent Henderson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

I. Kuss

26 papers receiving 963 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. Kuss United States	14	629	529	164	130	82	29	976
Hisanori Kashizuka Japan	9	417 0.7×	647 1.2×	105 0.6×	199 1.5×	246 3.0×	20	941
Yoshikazu Tsurui Japan	8	400 0.6×	669 1.3×	136 0.8×	186 1.4×	235 2.9×	14	934
Keishi Nakamura Japan	14	105 0.2×	227 0.4×	130 0.8×	168 1.3×	144 1.8×	57	585
Xiuwen Lan China	12	248 0.4×	394 0.7×	204 1.2×	166 1.3×	81 1.0×	17	696
Xiaosun Liu China	14	175 0.3×	267 0.5×	175 1.1×	207 1.6×	120 1.5×	25	647
Kyung Han Nam South Korea	14	99 0.2×	428 0.8×	227 1.4×	346 2.7×	137 1.7×	46	832
Jiren Yu China	19	205 0.3×	352 0.7×	285 1.7×	311 2.4×	230 2.8×	56	960
Chuntao Wu China	16	155 0.2×	431 0.8×	193 1.2×	116 0.9×	96 1.2×	30	686
Ching-Liang Ho Taiwan	13	140 0.2×	475 0.9×	251 1.5×	451 3.5×	116 1.4×	27	923
Tianyi Fang China	11	74 0.1×	236 0.4×	113 0.7×	173 1.3×	119 1.5×	37	463

Countries citing papers authored by I. Kuss

Since Specialization

Citations

This map shows the geographic impact of I. Kuss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Kuss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Kuss more than expected).

Fields of papers citing papers by I. Kuss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Kuss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Kuss. The network helps show where I. Kuss may publish in the future.

Co-authorship network of co-authors of I. Kuss

This figure shows the co-authorship network connecting the top 25 collaborators of I. Kuss. A scholar is included among the top collaborators of I. Kuss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Kuss. I. Kuss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crawford, E. David, Matthew R. Smith, Bertrand Tombal, et al.. (2022). LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL. The Journal of Urology. 207(Supplement 5). 1 indexed citations

Fizazi, Karim, Albertas Ulys, Egils Vjaters, et al.. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. Yearbook of pediatric endocrinology. 14 indexed citations

Fumagalli, Elena, Peter Reichardt, Yubin Kang, et al.. (2015). An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID). Annals of Oncology. 26. vi96–vi96.

Bauer, Sebastian, Jean‐Yves Blay, Paolo G. Casali, et al.. (2013). Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST). European Journal of Cancer. 49. 1 indexed citations

Casali, Paolo G., Peter Reichardt, Yoon‐Koo Kang, et al.. (2012). Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. Annals of Oncology. 23. ix478–ix479. 4 indexed citations

Reichardt, Peter, George D. Demetri, Yoon‐Koo Kang, et al.. (2012). Randomized phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) - GRID trial. Data Archiving and Networked Services (DANS). 35. 168–168.

Nishida, Toshirou, Paolo G. Casali, Peter Reichardt, et al.. (2012). Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial. Annals of Oncology. 23. xi20–xi20. 13 indexed citations

Kuss, I., Tony E. Godfrey, Robert L. Ferris, et al.. (2005). Recent thymic emigrants and subsets of naive and memory T cells in the circulation of patients with head and neck cancer. Clinical Immunology. 116(1). 27–36. 25 indexed citations

Kuss, I., et al.. (2004). Imbalance in Absolute Counts of T Lymphocyte Subsets in Patients with Head and Neck Cancer and Its Relation to Disease1. Advances in oto-rhino-laryngology. 62. 161–172. 53 indexed citations

10.

Bauernhofer, Thomas, F. Ploner, I. Kuss, et al.. (2003). Acute Pseudo-Obstruction of the Small Intestine Following High-Dose Chemotherapy and Stem Cell Support. Oncology Research and Treatment. 26(4). 344–346. 1 indexed citations

11.

Bauernhofer, Thomas, I. Kuss, U Friebe-Hoffmann, et al.. (2003). Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer. British Journal of Cancer. 88(8). 1301–1309. 13 indexed citations

12.

Kuss, I., Albert D. Donnenberg, William E. Gooding, & T L Whiteside. (2003). Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. British Journal of Cancer. 88(2). 223–230. 60 indexed citations

13.

Kuss, I., Hannah Rabinowich, William E. Gooding, Robert P. Edwards, & Theresa L. Whiteside. (2002). Expression of ζ in T Cells Prior to Interleukin-2 Therapy as a Predictor of Response and Survival in Patients with Ovarian Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 17(6). 631–640. 14 indexed citations

14.

Bauernhofer, Thomas, I. Kuss, Brent Henderson, Andrew S. Baum, & Theresa L. Whiteside. (2002). Preferential apoptosis of CD56^dim natural killer cell subset in patients with cancer. European Journal of Immunology. 33(1). 119–124. 136 indexed citations

15.

Bauernhofer, Thomas, Herbert Stöger, F. Ploner, et al.. (1999). Combined Treatment of Metastatic Osteosarcoma of the Spine. Oncology. 57(4). 265–268. 4 indexed citations

16.

Kuss, I., et al.. (1999). Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer.. PubMed. 5(2). 329–34. 111 indexed citations

17.

Samonigg, Hellmut, M. Wilders‐Truschnig, I. Kuss, et al.. (1999). A Double-Blind Randomized-Phase II Trial Comparing Immunization with Antiidiotype Goat Antibody Vaccine SCV 106 Versus Unspecific Goat Antibodies in Patients with Metastatic Colorectal Cancer. Journal of Immunotherapy. 22(6). 482–488. 19 indexed citations

18.

Stöger, Herbert, Marianne Schmid, Thomas Bauernhofer, et al.. (1994). A Phase II Trial of Weekly High-Dose Folinic Acid and 5-Fluorouracil in Combination with Epirubicin as Salvage Chemotherapy in Advanced Breast Cancer. Oncology. 51(6). 518–522. 3 indexed citations

19.

Bauernhofer, Thomas, Marianne Schmid, Ferdinand Ploner, et al.. (1994). A phase I/II study of 4?-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. Cancer Chemotherapy and Pharmacology. 35(2). 174–178. 1 indexed citations

20.

Samonigg, H., M. Wilders‐Truschnig, Hans Loibner, et al.. (1992). Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody. Clinical Immunology and Immunopathology. 65(3). 271–277. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact